Inside Precision Medicine

Obsessive-compulsive disorder is a psychiatric disorder affecting 1% of the U.S. population, but the underlying causes remain relatively unknown. However, recent research has highlighted potential genetic causes of this psychiatric outcome.

A tool that can pinpoint the location of detailed immune cell types in the human gut and lymph node, as well as map the fine-grained structure of the mouse brain has been developed by researchers based at the Wellcome Sanger Institute.

The deal provides $75 million upfront for Scorpion and has the potential to generate for the company as much as $1.5 billion in option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low-double digits.

Defining tumors by 'immune archetypes' rather than cancer type could result in cancer immunotherapies being more effective and precise in the future, suggests new research from University of California San Francisco (UCSF).

Researchers have discovered that a large subset of triple negative breast cancer expresses significant levels of MAPK4. Their studies showed that eliminating MAPK4 reduced human TNBC cell growth in animal models and sensitized the cells to therapies that block PI3K, a known cancer growth-promoting signaling pathway.

The launch of the clinical trial wholly sponsored by 23andMe is a pivotal achievement for the company’s therapeutic development division, which was started in 2015. But in 2020 GSK launched a trial of a drug candidate that came out of its collaboration with 23andMe, which started in 2018.

Of note in the recently released updated guidance, was information on the use of a human monoclonal antibody treatment regimen as a preventive measure against contracting COVID-19.

A combination of splice-switching antisense oligonucleotides could work against a common CFTR mutation that causes a severe form of cystic fibrosis, according to new research.

A new study by researchers from the department of twin research and genetic epidemiology, King’s College London, and the NIHR BioResource, has revealed genetic pathways underlying obesity.